Outcomes of tuberculosis at completion of ATT | |||
---|---|---|---|
Outcome | Nevirapine group | Efavirenz group | P value |
Ā | nā=ā67 | nā=ā68 | Ā |
Successfully treated | 50 (74.6%) | 51 (75.0%) | 0.26 |
Lost to follow up | 06 (9.0%) | 06 (8.8%) | |
Died | 11 (16.4%) | 09 (13.2%) | |
On ATT at end of study | 00 | 02 (2.9%) | |
Outcomes of ART after 24 months | |||
Outcome | Nevirapine group | Efavirenz group | P value |
nā=ā67 | nā=ā68 | ||
Mortality: | Ā | Ā | Ā |
Observed | 13 (19.4%) | 10 (14.7%) | 0.46 |
(% Adjusted for type of TB) | 19.1% | 14.9% | 0.50 |
ART failure: | 19 (28.4%) | 21 (30.9%) | 0.75 |
Clinical failure | 06 (9.0%) | 06 (8.8%) | 0.98 |
Immunological failure | 06 (9.0%) | 08 (11.8%) | 0.58 |
Virological failure | 10 (14.9%) | 09 (13.2%) | 0.94 |
Composite unfavourable outcome | 30 (44.8%) | 29 (42.6%) | 0.98 |
(Death and/or ART failure) |